The study analysed that the PTSD pipeline comprises of 23 drug candidates, of which one drug candidate is in the Phase III stage of development, two drug candidates are in the Phase II stage of development, seven drug candidates are in the Pre-Clinical stage of development, two drug candidates are in Discovery stage, one drug candidate is in Unknown Clinical stage, one drug candidate is in the Discontinued stage and nine drug candidates are Inactive. PTSD (PTSD) is a neurological disorder that develops in people who have experienced a scary or a dangerous event. PTSD can occur in a person at any age. According to the National Center of PTSD, around seven to eight out of 100 individuals experience PTSD at some point in their lives. Most of the people recover from traumatic situation naturally, but those who continue to experience problems are diagnosed with PTSD. People with PTSD are used to feel frightened even when they are not in a dangerous situation. PTSD generally occurs more often in women than men. Various collaboration between educational institutes, associations, and pharma companies are driving the therapeutic pipeline of PTSD.
Browse Report Description at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis
Many patents have been received during the development of drug candidates for the treatment of PTSD. In May 2017, Tonix reported the issuance of patent 9 636 408 by the United States Patent and Trademark Office titled “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Amitriptyline Hydrochloride,” covering the composition and manufacture of its proprietary sublingual formulation of very low dose cyclobenzaprine. Corcept Therapeutics, Inc. has rights to six U.S. composition of matter patents, which cover three distinct series of selective growth hormone receptor 2 antagonists, and also has a pending patent application. Three of these six patents have been granted in the Europe, while other three applications are pending. Patent expiry dates range from 2026 to 2032.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis/report-sample
Other key players developing drugs for the treatment of PTSD include One World Cannabis Ltd., Axim Biotechnologies, Inc., F. Hoffman-La-Roche AG, Therapade Technologies LLC, Neurocrine Biosciences, Inc. and Purdue Pharma L.P.
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY – 10016
Toll-Free: +1-888-778-7886 (USA/Canada)